A2 Biotherapeutics is designing novel cell therapies to treat serious illnesses. Therapeutics to treat cancers depend on methods to distinguish tumors from normal cells. A2 Bio is using their proprietary Tmod platform to innovate new treatments for solid tumors involving the immune system. The platform integrates multiple signals, overcoming conventional single-target therapies, and exploits tumor-specific vulnerabilities. The Tmod platform is robustly different from other cell therapy systems due to its tumor precision and efficacy by incorporating two receptors, an activator and a blocker, to modulate the immune system. As their platform is modular, A2 Bio is building a broad pipeline of both autologous and allogeneic cell therapies for many unexploited tumor targets. 

<p>A2 Biotherapeutics is designing novel cell therapies to treat serious illnesses. Therapeutics to treat cancers depend on methods to distinguish tumors from normal cells. A2 Bio is using their proprietary Tmod platform to innovate new treatments for solid tumors involving the immune system. The platform integrates multiple signals, overcoming conventional single-target therapies, and exploits tumor-specific vulnerabilities. The Tmod platform is robustly different from other cell therapy systems due to its tumor precision and efficacy by incorporating two receptors, an activator and a blocker, to modulate the immune system. As their platform is modular, A2 Bio is building a broad pipeline of both autologous and allogeneic cell therapies for many unexploited tumor targets. </p>


A2 Biotherapeutics

Tempus Announces Companion Diagnostic Collaboration with A2 Biotherapeutics

Cancer T-cell Therapy: Building the Foundation for a Cure

As September, Ovarian Cancer Awareness Month, comes to a close, it's important to reflect on the work being done to address this challenging disease. At A2 Bio, we're committed to advancing innovative treatments. We are currently testing A2B694 in the EVEREST-2 study (NCT06051695), a potential treatment for ovarian cancer in patients whose tumors express MSLN and have lost HLA-A*02. Our goal is to make a meaningful impact for those affected by this devastating illness. 

To read more about the EVEREST-2 study, please visit:  https://lnkd.in/gmbGrGjP

#OvarianCancerAwareness #CellTherapy #A2Bio

Explore Our Trials

A2 Biotherapeutics, Inc announced the acceptance of six abstracts for presentation at the Society for Immunotherapy of Cancer (SITC) annual meeting on November 8-10, 2024 in Houston.  We are especially proud to present safety and biomarker data on the EVEREST-1 (NCT05736731) study as well as an oral presentation highlighting continued progress in enhancing the diversity of patients enrolled in the BASECAMP-1 prescreening trial.  A2 Bio will also present progress on our EVEREST-2 trial (NCT06051695), and adaptations to boost potency and preserve selectivity of Tmod™ based cell therapies.  

For more information on our press release, please visit: https://lnkd.in/gvnFeWsK

For more information on our clinical studies, please visit: https://lnkd.in/ge7KqZ8T

#SITC #SITC2024
#A2Bio
#Tmod
#CellTherapy

The End of an Era of Cancer Drug Discovery: Life Without New Drug Targets

For Patients & Caregivers

VIEW ARTICLE 

 A2 Bio Highlights Progress of Tmod™ CAR T-Cell Clinical Programs During 2024 Annual Meeting of the Society for Immunotherapy of Cancer 

 Compositions and methods for treating cancers with hla-a*03 loss of expression 

Mesothelin-specific CAR-T Cell Therapy with HLA-gated Safety Mechanism Selectively Kills Tumor Cells

 Immune cells with paired receptors and uses thereof 

A2 Biotherapeutics Closes $71.5M Series B to Begin Clinical Development of its Potentially Transformative Selective Tumor Cell Therapeutics

 A2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directors 

 Compositions and methods for treating her2 positive cancers 

 A2 Biotherapeutics Closes $71.5M Series B Funding 

Improving Specificity of T-Cell Therapies in Solid Tumors: Julian Molina, MD, PhD

 C-Suite Shuffle: A2 Bio, Bayer, BioNTech and More 

Learn More About Our Clinical Trials

 Office Archives 

A2 Bio to Present Safety and Biomarker Data from EVEREST-1 Trial during 2024 Annual Meeting of the Society for Immunotherapy of Cancer - BioSpace

Cell therapy weekly: turning the attention of CAR-T to autoimmune disease - RegMedNet

 A2 Biotherapeutics Closes $80 Million Series C 

 LILRB1-based chimeric antigen receptor 

Scoop: A2 Biotherapeutics raises $62M for solid tumor cell therapies - Endpoints News

Watch this short video by Dr. Kristen Spencer, DO, Associate Professor, Department of Medicine at NYU Grossman School of Medicine and Director, Phase 1 Developmental Therapeutics Program, NYU Langone Perlmutter Cancer Center.  Dr. Spencer discusses the rationale for the phase 1/2 EVEREST-2 trial (NCT06051695) to evaluate a novel CAR T-cell product in pancreatic cancer. 

To view the OncLive TV video, please visit: https://lnkd.in/dv4d5i-P

For more information on our clinical studies, please visit:
https://lnkd.in/ge7KqZ8T

#OncLiveTV
#A2Bio #Tmod
#CellTherapy
#CART
#NYU

VIEW ABSTRACT 

March is Colorectal Cancer Awareness Month.  At A2 Bio, we're committed to advancing innovative oncology treatments for patients with colorectal cancer, leveraging our logic-gated Tmod™ CAR T-cell therapy. A2 Bio has two clinical studies, EVEREST-1 (NCT05736731) and EVEREST-2 (NCT06051695), that are actively enrolling patients with colorectal cancer, as well as other solid tumors. 

To read more about the EVEREST-1 and EVEREST-2 studies, please visit: 
https://lnkd.in/ge7KqZ8T

#ColorectalCancerAwarenessMonth 
#BlueForCRC
#A2Bio
#CellTherapy 

Best Places to Work - BioSpace

A2 Biotherapeutics Closes $80 Million Series C Financing to Advance Clinical Development of its Precision Cell Therapies Using its Proprietary Tmod(TM) Technology Platform

A2 Bio's William Go MD,PhD, Chief Medical Officer, will participate in a keynote panel on "Shaping the Future: CMO Insights on Strategic Evolution in Medical Affairs."  As a MD and Ph.D, he will discuss his experience with "bench to the bedside" in developing a comprehensive approach to product development.  As a clinical stage cell therapy company, A2 Bio is proud to participate in the Fierce Pharma Engage conference panel scheduled for Tuesday, April 29th from 1:00 - 2:00 pm PDT. 

For more information on our clinical studies, please visit:
https://lnkd.in/ge7KqZ8T

#FiercePharmaEngage
#A2Bio #Tmod
#CellTherapy

 A2 Biotherapeutics Closes $80 Million Series C Financing to Advance Clinical Development of Its Precision Cell Therapies Using Its Proprietary Tmod™ Technology Platform 

HLA-A*02:01-directed Chimeric Antigen Receptor/Forkhead Box P3-engineered CD4+ T cells Adopt a Regulatory Phenotype and Suppress Established Graft-versus-host Disease

A Rational Approach to Assess Off-Target Reactivity of a Dual-Signal Integrator for T Cell Therapy

A2 Bio recently closed out a successful conference at the Society for Immunotherapy of Cancer (SITC) 2024 in Houston, Texas.  Dr. Julian Molina, M.D., Ph.D. from Mayo Clinic, Rochester, MN, presented an oral presentation on the BASECAMP-1 prescreening study highlighting an innovative approach to overcome the operational burden of finding diverse participants for precision medicine studies.  A2 Bio presented 5 posters with updates on early safety and biomarker data from the ongoing EVEREST-1 (NCT05736731) clinical study and enrollment updates for the EVEREST-2 (NCT06051695) clinical study.  A2 Bio thanks the participants and clinical site teams for their support and partnership.  Looking forward to the SITC 2025 meeting in National Harbor, Maryland!

For more information on A2 Bio's press release, please visit: https://lnkd.in/gj5XFe7c

For more information on our clinical studies, please visit:
https://lnkd.in/ge7KqZ8T

#SITC #SITC2024
#A2Bio #Tmod
#CellTherapy



A2 Biotherapeutics Starts ‘Tmod’ Drug Clinical Trials - San Fernando Valley Business Journal

A2 Bio Announces First Patient Dosed in Phase 1 Clinical Trial of A2B530, a Novel Cell Therapy for the Treatment of Colorectal, Pancreatic and Non-small Cell Lung Cancers - Business Wire

 A2 Biotherapeutics nabs $71M-plus Series B for selective cell therapy pipeline 

Treating Solid Tumors With Personalized Immunotherapy: Julian Molina, MD, PhD

 A2 Bio Announces First Patient Dosed in EVEREST-2 Phase 1 Clinical Trial of Novel Mesothelin Logic-Gated CAR T 

A2 Bio recently published in the March 2025 edition of Frontiers of Immunology.  Dr. Breanna DiAndreth and her fellow A2 colleagues published new research showing that A2 Bio's Tmod™ platform can be extended beyond the dual-targeting approach for HLA LOH in solid tumors. Here, Tmod™ was designed to target 2-4 antigens to provide different practical and conceptual options for a blood cancer therapy.  The authors describe a Tmod™ construct designed to (1) improve the safety of CD33-targeted therapeutics and (2) extend the utility for a theoretically "universal" blood cancer therapy. 

For more information, please read the publication at: https://lnkd.in/g8CiubqZ

#A2Bio 
#Tmod
#CAR-TCellTherapy
#CellTherapy
#FrontiersinImmunology

A2 Bio's activator-blocker CAR-T cell therapies show early promise in solid cancers - Fierce Biotech

 A2 Bio’s new CEO aims to grow platform 

A2 Biotherapeutics Emerges From Stealth Mode With $57M Series A to Develop a Pipeline of Selective Tumor Cell Therapeutics

 A2 Bio Highlights Progress of CAR T-Cell Clinical Programs in Three Poster Presentations during the American Society ... 

 A2 Bio Receives FDA Orphan Drug Designation for Novel Cell Therapy Program A2B530 in Colorectal Cancer 

A2 Biotherapeutics, Inc. announces the acceptance of four posters for presentation at the American Association for Cancer Research annual meeting on April 25-30 in Chicago, Illinois.  We are especially proud to present clinical trial-in-progress data on the EVEREST-2 study (NCT06051695).  EVEREST-2 is a seamless phase 1/2 study of A2B694, a logic‑gated Tmod™ CAR T‑cell therapy, in patients with mesothelin‑expressing solid tumors with human leukocyte antigen‑A*02 loss of heterozygosity

For more information on our clinical studies, please visit: 
https://lnkd.in/ge7KqZ8T

#AACR2025
#A2Bio
#Tmod
#CellTherapy


A2 Biotherapeutics links up with Merck on Tmod candidate - The Pharma Letter

Engineered T-cells Directed at Tumors with Defined Allelic Loss

 A2 Biotherapeutics, Inc. on LinkedIn: #a2bio #biotechnews #oncologynews #celltherapy #asco24 

HLA-A∗02-gated Safety Switch for Cancer Therapy Has Exquisite Specificity for Its Allelic Target Antigen

 Articles about A2 Biotherapeutics 

 A2 Biotherapeutics Completes $80M Series C 

A2 Bio is honored to receive the MasterControl Innovation Excellence Award, accepted by QA Specialist Dan Lombardo. The award recognizes our groundbreaking Tmod™ cell therapy platform which uses logic-gating to distinguish between tumor and normal cells - a significant advancement in cancer treatment. We thank the MasterControl team for this recognition and continued partnership as we advance our innovative cell therapies. 

For more information, please review the MasterControl Quality Awards webpage: https://lnkd.in/gxnZTfry 


#A2Bio
#MCMastersSummit
#MastersOfExcellence
#InnovationExcellence
#Tmod
#CellTherapy

The Tmod Cellular Logic Gate As a Solution for Tumor-selective Immunotherapy

A2 Bio Announces First Patient Dosed in EVEREST-2 Phase 1 Clinical Trial of Novel Mesothelin Logic-Gated CAR T - Business Wire

A2 Bio will present a poster today titled, “Cytokine response and heme cell depletion and recovery after treatment with Tmod logic‑gated CAR Ts in patients with solid tumors,” at the SITC Spring Scientific, Cellular Therapy for Solid Tumors.

Please join A2 Bio and J. Randolph Hecht, MD, from the UCLA Jonsson Comprehensive Cancer Center, Thursday, March 13, 2025, 5-6:30 pm, at Poster #52 in the Aragon I Room, Rancho Bernardo Inn, San Diego, California.

After the event, the poster will be available on the A2 Bio's publications page: https://lnkd.in/g8CiubqZ

For more information on our clinical studies, please visit: https://lnkd.in/ge7KqZ8T

#SITCSpringScientific
#A2Bio #Tmod
#CellTherapy
#CART

Re-examination of MAGE-A3 as a T-cell Therapeutic Target

 Engineered immune cells with receptor cross-talk 

Agoura Hills biotech firm A2 Biotherapeutics moving to larger Conejo Valley headquarters - VC Star

 A2 Biotherapeutics Raises $80M Series C Funding 

A2 Biotherapeutics Closes $71.5M Series B To Begin Clinical Development Of Its Potentially Transformative Selective Tumor Cell Therapeutics - PR Newswire

 ScaleReady awards a $300,000 G-Rex® Grant to A2 Biotherapeutics, Inc. 

This week, we gathered to celebrate A2 Bio's 7th anniversary and reflect on how far we've come as a cell therapy company. The team enjoyed delicious food and cake to celebrate this achievement. Many thanks to our investors, Board of Directors, patients and their families, investigators and clinical staff in addition to our dedicated employees for helping us achieve this milestone. We are excited to keep the momentum going into 2025 and beyond.

#A2Bio
#CellTherapy
#Tmod

 Compositions and methods for treating egfr positive cancers 


                ScaleReady awards a $300,000 G-Rex® Grant to A2 Biotherapeutics, Inc.
              

Mesothelin-Specific CAR-T Cell Therapy that Incorporates an HLA-Gated Safety Mechanism Selectively Kills Tumor Cells

 A2 Bio to Highlight Progress of CAR T Clinical Programs in Three Poster Presentations at 2024 American Society of ... 

Robust In Vitro Pharmacology of Tmod, A Synthetic Dual-Signal Integrator for Cancer Cell Therapy

 Compositions and methods for treating mesothelin positive cancers 

A2 Biotherapeutics is proud to be a 2025 BioSpace "Best Places to Work" Winner!  This year, A2 ranked #5 among BioSpace's top 30 small employers.  We are incredibly proud that our dedication to finding a radical new way to treat solid tumors, our talented professionals, and the progress we are making as a clinical stage cell therapy company are being recognized across the industry.  

For more information on the BioSpace 2025 Best Places to Work in Life Sciences winners, please review the recent BioSpace announcement: https://lnkd.in/eVW6vt-2

For more information about A2 Bio, please visit:  https://www.a2bio.com/

#A2Bio 
#biospace 
#celltherapy
#BASECAMP-1
#EVEREST-1
#EVEREST-2

Breanna DiAndreth, PhD, on Improving Selective Targeting of Tumor Cells

A2 Biotherapeutics, Inc. will present four posters at the American Association for Cancer Research annual meeting in Chicago, Illinois.  

Sunday, April 27: 
Poster Title: A logic‑gated chimeric antigen receptor T cell (CAR T) for post‑transplant acute myeloid leukemia (AML) that distinguishes donor and recipient hematopoiesis
First Author:  Diane Manry
Abstract Number: 818
Poster Board Number: Section 34 - 6
Time: 2-5 pm CT

Monday, April 28: 
Poster Title: Signal 1 boosters that address the antigen‑access problem for solid tumor cell therapy
First Author: Diane Manry
Abstract Number: 3551
Poster Board Number: Section 39 - 27
Time: 2-5 pm CT

Tuesday, April 29: 
Poster Title: EVEREST‑2: A seamless phase 1/2 study of A2B694, a logic‑gated Tmod CAR T‑cell therapy, in patients with mesothelin‑expressing solid tumors with human leukocyte antigen‑A*02 loss of heterozygosity
First Author: Julian Molina
Abstract Number: CT186
Poster Board Number: Section 50 - 3
Time: 9 a - 12 p CT

Poster Title: Functional screen to optimize logic gate potency and selectivity
First Author: Sarah Martire
Abstract Number: 4072
Poster Board Number: Section 10 - 9
Time: 9 a - 12 p CT 

For more information on our clinical studies, please visit: 
https://lnkd.in/ge7KqZ8T

#AACR2025
#A2Bio
#Tmod
#CellTherapy


A2 Bio shared progress of its Tmod™ CAR T-cell clinical programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).  In an oral presentation today, A2 Bio shared progress in increasing diversity of participants enrolled in the BASECAMP-1 (NCT04981119) nationwide prescreening study for all Tmod™ CAR T-cell trials.  The company also presented posters highlighting early safety and biomarker data from the ongoing EVEREST-1 trial (NCT05736731), enrollment updates for the EVEREST-2 trial (NCT06051695), and updates on adaptations to boost potency and preserve selectivity of its Tmod™ -based precision cell therapies.  

For more information on A2 Bio's press release, please visit: https://lnkd.in/gj5XFe7c

For more information on our clinical studies, please visit: https://lnkd.in/ge7KqZ8T

#SITC #SITC2024
#A2Bio #Tmod
#CellTherapy

Extensive Functional Comparisons Between Chimeric Antigen Receptors and T-cell Receptors Highlight Fundamental Similarities

FierceBiotech
A2 Bio’s Activator-blocker CAR-T Cell Therapies Show Early Promise in Solid Cancers 

For Healthcare Providers

Genomic Immune Evasion: Diagnostic and Therapeutic Opportunities in Head and Neck Squamous Cell Carcinomas

A2 Bio Highlights Progress of Tmod™ CAR T-Cell Clinical Programs During 2024 Annual Meeting of the Society for Immunotherapy of Cancer - Business Wire

 A2 Biotherapeutics Raises $80M Series C 

 Engineered immune cells with receptor signal strength modulated by a hinge 

C-Suite Shuffle: A2 Bio, Bayer, BioNTech and More - BioSpace

 Scoop: A2 Biotherapeutics raises $62M for solid tumor cell therapies 

New tenant puts Agoura Hills on map as part of Conejo Valley biotech hub - The Acorn

Happy Halloween!  A2 Bio recently hosted a Halloween kids parade and potluck party at our offices in Agoura Hills, CA.  Team members dressed up and participated in a costume contest.  Teamwork is a core value at A2 Bio, and it was on full display yesterday.  

To learn more about our company and team, please visit: https://www.a2bio.com/

#A2Bio #Teamwork #Halloween  #CellTherapy

A2 Bio publishes key preclinical findings demonstrating potential of its highly selective Tmod™ cell therapy platform to revolutionize the treatment of solid tumors in select patients - BioSpace

The Future of Logic-gated Cell Therapy

Structure-function Relationships of Chimeric Antigen Receptors in Acute T-cell Responses to Antigen

A2 Biotherapeutics Enters into Collaboration Agreement with Merck to Develop Allogeneic Cell Therapy for Solid Tumor Cancers

March is national Kidney Cancer Awareness month.  A2 Bio is focused on developing cell therapies that target solid tumors such as kidney cancer.  Our BASECAMP-1 (NCTO4981119) pre-screening study is currently enrolling patients with renal cell carcinoma and other solid tumors.  BASECAMP-1 is a non-interventional study that leverages clinical diagnostics to efficiently identify patients eligible for our interventional trials.  

For more information on our clinical studies, please visit:
https://lnkd.in/ge7KqZ8T

#KidneyCancerAwarenessMonth
#A2Bio #Tmod
#CellTherapy

A Carcinoembryonic Antigen-specific Cell Therapy Selectively Targets Tumor Cells with HLA Loss of Heterozygosity in Vitro and In Vivo

A2 Bio’s Screening Study Identifies Eligible Patients for Treatment With Tmod CAR-T - CGTLive™

 Innovative Targeting Solutions and Former Amgen Executive Team up to Launch A2 Biotherapeutics With a $57 Million Series A 

 Cell therapy startup A2 Biotherapeutics nets $80M Series C 

A2 Biotherapeutics uncloaks with $57M and tumor- ...

The A2 Bio Volunteer Club recently participated in the L.A. Cancer Challenge (LACC) at UCLA.  Our team, led by Will Go, MD, PhD, Chief Medical Officer, received a Gold Medal for raising over $2,500! The LACC, organized by the Agi Hirshberg Foundation (pictured with Drs. Donahue, Wainberg and Go), raised over $600,000 to fund cancer research and programs designed to improve patient care, offer better treatment options, and ultimately find a cure for pancreatic cancer.  Special thanks to the A2 Bio staff who participated in the event and contributed to support the Agi Hirshberg Foundation. 

To learn more about A2 Bio's clinical studies, please visit: https://lnkd.in/ge7KqZ8T

#A2Bio #run4cure #run2endpc #LACancerChallenge

November is Pancreatic Cancer Awareness Month.  At A2 Bio, we're committed to advancing innovative oncology treatments leveraging our logic-gated Tmod™ CAR T-cell therapy. A2 Bio has two current clinical studies, EVEREST-1 (NCT05736731) and EVEREST-2 (NCT06051695), that are actively enrolling patients with pancreatic cancer, as well as other solid tumors. Our company and staff are dedicated to making a meaningful impact for those affected by this devastating illness. 

To read more about the EVEREST-1 and EVEREST-2 studies, please visit: 
https://lnkd.in/ge7KqZ8T

#PancreaticCancerAwareness #SupportPancreaticCancer #HopeForACure #CellTherapy #A2Bio

Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers

A2 Biotherapeutics

Business:

Drug notes:

About: